Engineered Ultrasmall Nanoparticle Drug-Immune Conjugates with "Hit and Run" Tumor Delivery to Eradicate Gastric Cancer
Li Zhang,Virginia Aragon-Sanabria,Anusha Aditya,Marcello Marelli,Tianye Cao,Feng Chen,Barney Yoo,Kai Ma,Li Zhuang,Thais Cailleau,Luke Masterson,Melik Z Turker,Rachel Lee,Gabriel DeLeon,Sebastien Monette,Raffaele Colombo,Ronald J Christie,Pat Zanzonico,Ulrich Wiesner,J Anand Subramony,Michelle S Bradbury
DOI: https://doi.org/10.1002/adtp.202370009
Abstract:Despite advances by recently approved antibody-drug conjugates in treating advanced gastric cancer patients, substantial limitations remain. Here, several key obstacles are overcome by developing a first-in-class ultrasmall (sub-8-nanometer (nm)) anti-human epidermal growth factor receptor 2 (HER2)-targeting drug-immune conjugate nanoparticle therapy. This multivalent fluorescent core-shell silica nanoparticle bears multiple anti-HER2 single-chain variable fragments (scFv), topoisomerase inhibitors, and deferoxamine moieties. Most surprisingly, drawing upon its favorable physicochemical, pharmacokinetic, clearance, and target-specific dual-modality imaging properties in a "hit and run" approach, this conjugate eradicated HER2-expressing gastric tumors without any evidence of tumor regrowth, while exhibiting a wide therapeutic index. Therapeutic response mechanisms are accompanied by the activation of functional markers, as well as pathway-specific inhibition. Results highlight the potential clinical utility of this molecularly engineered particle drug-immune conjugate and underscore the versatility of the base platform as a carrier for conjugating an array of other immune products and payloads.